Evolving concepts concerning cardiac β-adrenoceptor function in heart failure.
This review describes the clinical application of β-adrenergic blocking drugs over time in patients with congestive heart failure. The different pharmacological properties of these drugs in relation to clinical outcomes raises questions as to their optimal desirable profile based on studies showing the undesirable effects of excessive β(2)-AR activation. The rationale for the use of selective β(2)-AR antagonists in heart failure is discussed.